STAT3 and diffuse large B-cell lymphoma: A phase I/II is currently being performed in patients with advanced tumors, including refractory DLBCL, evaluating the clinical efficacy and safety of ISIS-STAT3Rx, an antisense oligonucleotide, which inhibits nuclear translocation of STAT3 (NCT01563302).